N/A N=90 Home-based Resistance Training to Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Physical Activity — 59.98; 48.21; 59.43 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam
Dermatitis
Primary: Number of Partecipants With Improvement of Dermatitis Severity — 37 Participants
N/A N=100 LSA Reconstruction With Laser Fenestration During the TEVAR
Type B Aortic Dissection
Primary: Freedom From All-cause Reintervention, All-cause Mortality and Major Adverse Events Within 30 Days After Procedure — 84 Participants
Phase 2 N=255 Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects
Alzheimer's Disease
Primary: Change From Baseline in Repeatable Battery for the Assessment of Neurological Status- Delayed Memory Index (RBANS- DMI) at Week 13 — 10.1; 9.9; 9.7 scores on a scale
Phase 2 N=160 A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure
Hypertension
Primary: Change From Baseline in Seated Automated Office SBP to Day 85 — -9; -13; -9 mmHg — p==0.135
Phase 3 N=8 A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
Heart Failure
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 1 Participants
Early Phase 1 N=453 Endovascular Recanalization and Standard Medical Management for Symptomatic Nonacute Intracranial Artery Occlusion Trial
Intracranial Artery Occlusion With Infarction
Primary: Primary Outcome — 27; 21 Participants
Phase 2 N=337 Tezepelumab COPD Exacerbation Study
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Rate of Moderate or Severe COPD Exacerbations in Participants With Moderate to Very Severe COPD. — 1.75; 2.11 exacerbations per year — p=0.1042
N/A N=19 Pilot Study of Nursing Touch and Biobehavioral Stress
Prematurity · Stress Reaction
Primary: Average Heart Rate -- During Intervention — 172.6; 168.6 beats per minute
N/A N=20 Prospective Feasibility Study Evaluating EchoMark LP Placement and EchoSure Measurements for Subjects Requiring Arteriovenous Fistulae
Kidney Diseases · Arteriovenous Fistula
Primary: Primary Safety Endpoint — 0 MAES within 30 days post baseline visit
N/A N=10,644 GeneXpert Performance Evaluation for Linkage to Tuberculosis Care
Tuberculosis, Pulmonary · Rifampicin Resistant Tuberculosis
Primary: Number Treated for Microbiologically-confirmed TB Within 14 Days After Presentation to the Health Center for TB Evaluation — 220; 342 Participants
Phase 2 N=77 A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
Atopic Dermatitis
Primary: Achievement of 75% Reduction From Baseline in the Eczema Area and Severity Index (EASI 75 Response) at Week 12 (Day 84) — 32.3; 37.4 Percentage (%)
Phase 2 N=14 Metformin to Reduce Airway Glucose in COPD Patients
Chronic Obstructive Pulmonary Disease
Primary: Sputum Glucose Concentration — 68.92; 12.2 µM
Phase 2 N=25 Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease
Sickle Cell Disease
Primary: Mean Change From Baseline in Haemolysis Marker (Indirect Bilirubin) — 24.0; 56.4; 44.0; 31.2 micromoles per liter (umol/L)
Phase 3 N=436 Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome
Cutaneous Malignant Melanoma
Primary: Relapse Free Survival — 41; 32 Participants — p== 0.324